The Diagnostic Yield and Implications of Targeted Founder Pathogenic Variant Testing in an Israeli Cohort

Founder pathogenic variants (PVs) are prevalent in Israel. This study investigated the current practice of offering cancer patients two-step genetic testing, starting with targeted testing for recurring founder PVs, followed, if negative, by next-generation sequencing. A total of 2128 subjects with...

Full description

Saved in:

Bibliographic Details
Published in:	Cancers 2023-12, Vol.16 (1), p.94
Main Authors:	Abu Shtaya, Aasem, Kedar, Inbal, Mattar, Samar, Mahamid, Ahmad, Basel-Salmon, Lina, Farage Barhom, Sarit, Naftaly Nathan, Sofia, Magal, Nurit, Azulay, Noy, Levy Zalcberg, Michal, Chen-Shtoyerman, Rakefet, Segol, Ori, Seri, Mor, Reznick Levi, Gili, Shkedi-Rafid, Shiri, Vinkler, Chana, Netzer, Iris, Hagari Bechar, Ofir, Chamma, Liat, Liberman, Sari, Goldberg, Yael
Format:	Article
Language:	English
Subjects:	Adenomatous polyposis coli Breast cancer Cancer Ethnicity Exercise tests Family medical history Genetic counseling Genetic screening Genetic testing Heterozygotes Jewish people Jews Medical diagnosis Medical tests Minority & ethnic groups Next-generation sequencing Oncology, Experimental Ovarian cancer Pancreatic cancer Population
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!